Category - Developments

Developments

Profound Medical to present TULSA-PRO 3-year outcomes and BPH subgroup analysis

Three-year clinical outcomes and a subgroup analysis of benign prostatic hyperplasia (BPH) patients enrolled in Profound Medical’s (TSX:PRN; OTCQX:PRFMF) earlier Phase 1 safety and feasibility study of TULSA-PRO will be...

September 19, 2018

Developments

CellAegis completes enrollment in heart attack study with autoRIC

Closely-held CellAegis Devices completed enrollment in an investigator sponsored study (FIRST) to evaluate the clinical and economic benefits of remote ischemic conditioning (RIC) therapy in the treatment of patients...

September 11, 2018

Developments

Titan Pharma receives NIDA grant for nalmefene implant to prevent opioid addiction relapse

Titan Pharmaceuticals (NASDAQ:TTNP) was awarded a two-year grant of about $6.7-million from the NIH’s National Institute on Drug Abuse (NIDA) for the development of a ProNeura-based six-month implantable formulation of...

September 10, 2018

Developments

Mati Therapeutics posts positive interim Phase 2 nepafenac results in cataract surgery pain reduction

Closely-held Mati Therapeutics reported encouraging results from a planned interim analysis of an ongoing Phase 2 clinical trial evaluating the safety and efficacy of nepafenac delivered in Mati’s Evolute sustained...

September 10, 2018

Developments

Ortho RTi in pact with CMO to manufacture cGMP quantities of Ortho-R

Ortho Regenerative Technologies (CSE:ORTH) entered into an agreement with a leading contract manufacturing organization operating within the global biopharmaceutical industry to begin work on providing Ortho RTi with...

September 6, 2018

Developments

Titan, Nevada Center for Behavioral Health collaborate on Probuphine treatment of OUD in criminal justice system

Titan Pharmaceuticals (NASDAQ:TTNP) launched a pilot program in collaboration with the Nevada Center for Behavioral Health to evaluate a medication-assisted treatment program utilizing Titan’s Probuphine (buprenorphine)...

September 4, 2018

Developments

Urovant Sciences licenses gene therapy for overactive bladder

Closely-held Urovant Sciences licensed from Ion Channel Innovations global rights for an investigational gene therapy, hMaxi-K, for patients with overactive bladder (OAB) symptoms, who have failed oral pharmacologic...

August 28, 2018

Developments

Esperion posts positive Phase 3 bempedoic acid/ezetimibe combo results

Esperion (NASDAQ:ESPR) reported positive top-line results from a Phase 3 study of its bempedoic acid/ezetimibe combination pill for the treatment of LDL-C lowering. The study included 382 high-risk patients taking...

August 28, 2018

Developments

Sierra Oncology acquires momelotinib from Gilead

Sierra Oncology (NASDAQ:SRRA) has acquired the drug candidate, momelotinib, from Gilead Sciences (NASDAQ:GILD) for a $3-million upfront fee and potential milestone payments of up to $195-million, which are largely...

August 22, 2018

Developments

FDA accepts Evoke Pharma NDA for Gimoti; PDUFA date April 1

The FDA has accepted for review Evoke Pharma’s (NASDAQ:EVOK) 505(b)(2) NDA for Gimoti, the company’s nasal spray product candidate for the relief of symptoms in adult women with acute and recurrent diabetic...

August 16, 2018

Category - Developments

Subscribe